Pharmacokinetics in Drug Development: Advances and Applications, Volume 3
Sold by HPB-Red, Dallas, TX, U.S.A.
AbeBooks Seller since 11 March 2019
Used - Hardcover
Condition: Used - Good
Ships within U.S.A.
Quantity: 1 available
Add to basketSold by HPB-Red, Dallas, TX, U.S.A.
AbeBooks Seller since 11 March 2019
Condition: Used - Good
Quantity: 1 available
Add to basketConnecting readers with great books since 1972! Used textbooks may not include companion materials such as access codes, etc. May have some wear or writing/highlighting. We ship orders daily and Customer Service is our top priority!
Seller Inventory # S_352831062
The topics chosen for this volume were selected because they are some of the current development or technological issues facing drug development project teams. They regard the practical considerations for assessment of selected special development populations. For example, they include characterization of drug disposition in pregnant subjects, for measuring arrhythmic potential, for analysis tumor growth modeling, and for disease progression modeling. Practical considerations for metabolite safety testing, transporter assessments, Phase 0 testing, and development and execution of drug interaction programs reflect current regulatory topics meant to address enhancement of both safety assessment and early decision-making during new candidate selection. Important technologies like whole body autoradiography, digital imaging and dried blood spot sample collection methods are introduced, as both have begun to take a more visible role in pharmacokinetic departments throughout the industry.
Peter Bonate has 16 years industrial experience, 13 years as a clinical pharmacologist/pharmacokineticist and 3 years in drug metabolism and bioanalysis. He is currently a Director in the Clinical Pharmacology, Modeling, and Simulation department at GlaxoSmithKline in the oncology therapeutic area. He has also worked at Genzyme, Hoechst Marion Roussel, Eli Lilly, and Quintiles. He received his Ph.D. in 1996 from Indiana University in Medical Neurobiology with an emphasis on the pharmacokinetics of drugs of abuse. He received an MS in statistics from the University of Idaho and an MS in Pharmacology from Washington State University both in 1990. In 2003 he was elected a Fellow of the American College of Clinical Pharmacology and in 2007 was elected a fellow of the American Association of Pharmaceutical Scientists (AAPS). He was founder of the Modeling and Simulation focus group, has served as chair of the population pharmacokinetics focus group, and was section leader for the Clinical Pharmacology and Translational Research Section within AAPS. He has served or currently serves on the editorial boards for the Journal of Clinical Pharmacology, Pharmaceutical Research, Journal of Pharmacokinetics and Pharmacodynamics, and the AAPS Journal. He has more than 40 publications in the field of pharmacokinetics and clinical pharmacology, is co-editor of the 2-volume series Pharmacokinetics in Drug Development published by AAPS Press in 2004, and is author of the book Pharmacokinetic-Pharmacodynamic Modeling and Simulation published by Springer in 2005.
Danny Howard received his Bachelor's of Science degree in Pharmacy, and Ph.D. from the University of Missouri in Kansas City. He began working in the pharmaceutical industry in 1991, first as a biopharmaceutics consultantand then as pharmaceutical scientist for Marion Merrell Dow, Hoechst Marion Roussel, Aventis, and Quintiles. He is currently the Vice President of Global Pharmacokinetics and Pharmacodynamics for Novartis. His career has included responsibilities in both clinical and nonclinical pharmacokinetics and pharmacodynamics, bioanalytics, and pharmaceutical business operations. He has worked with numerous drug submissions supporting both large and small molecules worldwide. He was a charter member of the Missouri Biotech Association and served as its first Board Chairman. With Peter Bonate, he was the co-editor of the series Pharmacokinetics in Drug Development published by AAPS Press in 2004.
"About this title" may belong to another edition of this title.
If you are a consumer you can cancel the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.
INFORMATION REGARDING THE RIGHT OF CANCELLATION
Statutory Right to cancel
You have the right to cancel this contract within 14 days without giving any reason.
The cancellation period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the the last good or the last lot or piece.
To exercise the right to cancel, you must inform us, HPB-Red, 5803 E. Northwest Hwy., 75231, Dallas, Texas, U.S.A., +1 214-819-9556, of your decision to cancel this contract by a clear statement (e.g. a letter sent by post, fax or e-mail). You may use the attached model cancellation form, but it is not obligatory. You can also electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". If you use this option, we will communicate to you an acknowledgement of receipt of such a cancellation on a durable medium (e.g. by e-mail) without delay.
To meet the cancellation deadline, it is sufficient for you to send your communication concerning your exercise of the right to cancel before the cancellation period has expired.
Effects of cancellation
If you cancel this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).
We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.
We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to cancel with contract.
We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.
We may withhold reimbursement until we have received the goods back or you have supplied evidence of having sent back the goods, whichever is the earliest.
You shall send back the goods or hand them over to us or HPB-Red, 3860 La Reunion Pkwy., 75212, Dallas, Texas, U.S.A., +1 214-819-9556, without undue delay and in any event not later than 14 days from the day on which you communicate your cancellation from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.
Exceptions to the right of cancellation
The right of cancellation does not apply to:
Model withdrawal form
(complete and return this form only if you wish to withdraw from the contract)
To: (HPB-Red, 5803 E. Northwest Hwy., 75231, Dallas, Texas, U.S.A., +1 214-819-9556)
I/We (*) hereby give notice that I/We (*) withdraw from my/our (*) contract of sale of the following goods (*)/for the provision of the following goods (*)/for the provision of the following service (*),
Ordered on (*)/received on (*)
Name of consumer(s)
Address of consumer(s)
Signature of consumer(s) (only if this form is notified on paper)
Date
* Delete as appropriate.
| Order quantity | 4 to 14 business days | 2 to 6 business days |
|---|---|---|
| First item | £ 2.79 | £ 5.19 |
Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.